Citius Oncology Completes Distribution Network for LYMPHIR with McKesson Partnership Ahead of Q4 2025 Launch
核心洞察
Citius Oncology (搜索) has finalized a distribution agreement with McKesson Corporation, completing its U.S. distribution network for LYMPHIR (denileukin diftitox-cxdl) with all three largest pharmaceutical distributors in the country.
The partnership positions LYMPHIR for its planned fourth quarter 2025 commercial launch, targeting the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (搜索) after at least one prior systemic therapy.
LYMPHIR received FDA approval in August 2024 as a targeted immunotherapy that combines IL-2 receptor (搜索) binding with diphtheria toxin fragments to selectively kill cancer cells expressing IL-2 receptors.
Citius Oncology (搜索) has secured a distribution agreement with McKesson Corporation, completing its comprehensive U.S. distribution network for LYMPHIR (denileukin diftitox-cxdl) ahead of the therapy's planned commercial launch in the fourth quarter of 2025. The partnership with McKesson, one of North America's largest pharmaceutical distributors, represents the final component of Citius Oncology's distribution strategy for the FDA-approved immunotherapy targeting cutaneous T-cell lymphoma (搜索).
Strategic Distribution Network Completion
The agreement with McKesson completes Citius Oncology (搜索)'s core U.S. distribution network, which now includes all three of the largest pharmaceutical distributors in the country. This strategic milestone ensures broad and reliable access to LYMPHIR across both academic centers and community oncology practices nationwide.
"This agreement marks the final major component of our U.S. distribution strategy and reflects our deep commitment to ensuring that physicians and patients have timely access to LYMPHIR," said Leonard Mazur, Chairman and CEO of Citius Oncology (搜索) and Citius Pharmaceuticals. "With a complete top-tier distribution network in place, we believe we are well-positioned to deliver on our promise to the CTCL (搜索) community and execute a successful launch."
McKesson Corporation, headquartered in Irving, Texas, serves as a global leader in healthcare supply chain management, medical products distribution, and pharmaceutical logistics. The company supports thousands of hospitals, clinics, and pharmacies across the United States, making it a critical partner for enabling access to specialized therapies like LYMPHIR.
LYMPHIR's Mechanism and Clinical Profile
LYMPHIR is a targeted immune therapy indicated for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (搜索) after at least one prior systemic therapy. The drug functions as a recombinant fusion protein that combines the IL-2 receptor (搜索) binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis, ultimately resulting in cell death.
The therapy demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and showed antitumor activity through direct cytocidal action on IL-2R-expressing tumors. LYMPHIR received FDA approval in August 2024, following earlier regulatory approval in Japan in 2021 for the treatment of CTCL (搜索) and PTCL.
Market Opportunity and Commercial Readiness
Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and remains underserved by existing therapies. The company's commercialization efforts extend beyond distribution agreements to include inventory readiness, market access infrastructure, permanent J-code assignment (J9161), NCCN guideline inclusion, and comprehensive provider and patient education resources.
Citius Oncology (搜索)'s intellectual property protections span orphan drug designation, complex technology, trade secrets, and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors, supporting the company's competitive positioning in the CTCL (搜索) treatment landscape.
Safety Profile and Clinical Considerations
LYMPHIR carries a boxed warning for capillary leak syndrome (搜索) (CLS), including life-threatening or fatal reactions. In pooled clinical trial data across three studies, CLS occurred in 27% of patients, including 8% with Grade 3 severity. There was one fatal occurrence of CLS (0.8%). The majority of CLS events (81%) occurred within the first two cycles of treatment, with a median time to onset of 6.5 days and median duration of 14 days.
Additional significant adverse events include visual impairment, which occurred in 9% of patients, and infusion-related reactions, reported in 69% of patients. Hepatotoxicity represents another concern, with elevated ALT occurring in 70% of patients and Grade 3 ALT elevation in 22% of patients. The most common adverse reactions include increased transaminases, decreased albumin, nausea, edema, decreased hemoglobin, fatigue, musculoskeletal pain, rash, chills, constipation, pyrexia, and capillary leak syndrome (搜索).
Disease Background and Unmet Need
Cutaneous T-cell lymphoma (搜索) represents the most common type of cutaneous lymphoma, affecting men twice as often as women and typically diagnosed in patients between ages 50 and 60. The disease involves T-cells becoming cancerous and developing into skin lesions, leading to decreased quality of life due to severe pain and pruritus. Mycosis Fungoides (搜索) and Sézary Syndrome (搜索) comprise the majority of CTCL (搜索) cases.
The disease may progress slowly over several years to potentially reach tumor stage, but once advanced, the cancer becomes highly malignant and can spread to lymph nodes and internal organs, resulting in poor prognosis. Given the chronic nature of the disease, patients typically cycle through multiple agents to control disease progression. Other than allogeneic stem cell transplantation, for which only a small fraction of patients qualify, there is currently no curative therapy for advanced CTCL (搜索).